N/A N=314 Primary Immunodeficiency in Kuwait
Primary Immune Deficiency Disorder
Primary: Number of Participants With Different Epidemiological Features — 287; 100; 68; 56 patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=48 Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
N/A N=308 COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
N/A N=1,086 Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
Secondary Immunodeficiencies (SID)
Primary: Guideline Adherence (GLAD) — 889; 75; 122 Participants
Phase 2 N=47 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Phase 3 N=25 Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
Primary Immune Deficiency Disorder
Primary: Number of Serious Bacterial Infections Per Person-Year on Treatment — 0 SBI per patient year
Phase 3 N=271 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Human Papilloma Virus · Hiv · Organ Transplants
Primary: Seroconversion Following 3 Doses of 9-valent HPV Vaccines — 100; 64.2; 100; 70.7 Percentage of participants
N/A N=133 Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Infections After Lung Transplant
Primary: The Primary Outcome Will be the Total Number of Days With Pneumonia. — 1714; 51 Number of days
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Phase 4 N=539 COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
Covid19
Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…
Phase 2 N=21 A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency
Immunologic Deficiency Syndrome
Primary: Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG) — 7549; 6706 mg*hr/ml
Phase 3 N=49 Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Immunologic Deficiency Syndromes
Primary: The Incidence of Acute Serious Bacterial Infections (SBI) — 0.04; 0; 0.02 Number of events per patient per year
Phase 3 N=55 Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Agammaglobulinemia · IgG Deficiency · Common Variable Immunodeficiency
Primary: The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs). — 0.073; 0.141; 0.150 Proportion of infusions
N/A N=1,277,747 COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
Immunocompromised · Immunosuppressed · Covid-19
Primary: Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection — 0.89; 0.34 Events per 100 person-years
Phase 3 N=64 Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Primary Immune Deficiency Disorder
Primary: IgG Trough Levels From Baseline to End of Study (28 Weeks) — 0.144; 0.065; -0.593 g/L
Phase 3 N=75 Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Primary Immunodeficiency
Primary: Annual Rate of Occurrence of Serious Bacterial Infections (SBI) — 0; 0.01; 0; 0.03 Rate of events per subject per year
Phase 3 N=63 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Primary Immune Deficiency Disorders (PIDD)
Primary: Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment — 0.035 SBIs Per Total Person-Years
Phase 3 N=51 A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases
Primary Immunodeficiency Diseases
Primary: Number of Serious Bacterial Infections Per Person-year of Treatment — 0.080 Serious infections per person-year of tr
Phase 2 N=29 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
Immunodeficiency Syndrome · Non-Cancer Diagnosis
Primary: Number of Patients Who Achieve Greater Than 50% Donor T-cell Chimerism — 13 Participants
N/A N=29 Thymus Transplantation Safety-Efficacy
Complete DiGeorge Anomaly · DiGeorge Syndrome · DiGeorge Anomaly
Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants
N/A N=30 Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder
Hematologic Diseases · Secondary Immune Deficiency
Primary: Infusion Time of Multigam IV 5% and Multigam IV 10% — 4.92; 2.29 hour — p=<0.0001
Phase 4 N=11 Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
Primary Immunodeficiency
Primary: Steady-state Area Under the Curve (AUC) for Serum Total Immunoglobulin (IgG) — 216873.7; 230830.0 h*mg/dL
Phase 4 N=18 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Common Variable Immunodeficiency · Agammaglobulinemia
Primary: Proportion of Patients Achieving Immunoglobulin G (IgG) Levels ≥ 5 g/L on Day 12 — 0.944 proportion of patients
Phase 3 N=98 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Primary Immune Deficiency Disorder · Hematopoietic Stem Cell Transplantation
Primary: Overall Survival — 86; 86; 87 percentage of survival probability — p=0.95
Phase 3 N=50 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Primary Immunodeficiency · Common Variable Hypogammaglobulinemia · X-linked Hypogammaglobulinemia
Primary: Number of Serious, Acute, Bacterial Infections (SABIs) Per Subject Per Year in Subjects With Primary Immunodeficiency Disease. — 0 SABIs/subject/year — p=0.01
Phase 4 N=11 Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
Primary: Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired…
Phase 4 N=280 Immunomodulation Following Transfusion
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
Phase 2 N=31 Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month — 0 Participants
Phase 3 N=21 Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
Primary Immune Deficiency
Primary: Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population) — 0.06 infections per subject year
Phase 3 N=52 Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
Primary Immunodeficiency
Primary: AUC in the IV Phase and SC Phases: Steady-state AUC of Total IgG Over a Regular Dosing Interval — 207921.5; 213141.4 h*mg/dL